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Available online 24 September 2016Single-cell based ampliﬁcation of immunoglobulin variable regions is a rapid and powerful technique for cloning
antigen-speciﬁc monoclonal antibodies (mAbs) for purposes ranging from general laboratory reagents to thera-
peutic drugs. From the initial screening process involving small quantities of hundreds or thousands of mAbs
through in vitro characterization and subsequent in vivo experiments requiring large quantities of only a few,
having a robust system for generating mAbs from cloning through stable cell line generation is essential. A pro-
tocolwas developed to decrease the time, cost, and effort required by traditional cloning and expressionmethods
by eliminating bottlenecks in these processes. Removing the clonal selection steps from the cloning process using
a highly efﬁcient ligation-independent protocol and from the stable cell line process by utilizing bicistronic plas-
mids to generate stable semi-clonal cell pools facilitated an increased throughput of the entire process from plas-
mid assembly through transient transfections and selection of stable semi-clonal cell pools. Furthermore, the
time required by a single individual to clone, express, and select stable cell pools in a high-throughput format
was reduced from 4 to 6 months to only 4 to 6 weeks.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The rapid production of monoclonal antibodies (mAbs) isolated
from an immunized organism is essential for the development of thera-
peutic and diagnostic reagents and critical in the support of vaccine
studies. Traditional methods for the production and screening of mAbs
involving hybridomas or EBV transduction (Aman et al., 1984; Beerli
and Rader, 2010; Kohler and Milstein, 1975; Kozbor et al., 1982;
Redmond et al., 1986; Stahli et al., 1980; Steinitz et al., 1977; Striebich
et al., 1990; Strohl, 2014) are inefﬁcient due to genomic instability and
lowmAb expression of the resulting cell lines. To circumvent these lim-
itations, technologies have been developed to clone variable domain
genes into a phage, yeast, ribosomal, or mammalian display platform
(Beerli and Rader, 2010; Lim et al., 2014; Saggy et al., 2012; Strohl,
2014). PCR ampliﬁed variable heavy (VH) and light (VL) regions from
an immunized organism are randomly paired in a library that is
screened for antigen binding, and, subsequently, the top binding VH-
VL region pairs are subcloned into mammalian expression plasmids
for large-scale production. While antibody display technologies are
powerful techniques, generating a quality library is limited by the efﬁ-
ciencies of the random VH-VL pairing (not all pairs result in optimal. This is an open access article underantigen binding) and cloning process and poor expression/enrichment
of many relevant antigen speciﬁc V genes (Saggy et al., 2012).
To overcome the limitations associated with hybridoma/immortal
cell lines and combinatorial display platforms, new techniques have
been developed to isolate and clone variable region cDNAs from anti-
gen-speciﬁc single B cells into antibody expression vectors (Scheid et
al., 2009; Smith et al., 2009; Tiller et al., 2009; Tiller et al., 2008; Tiller
et al., 2007; Wardemann et al., 2003; Wrammert et al., 2008). Since
the heavy (HC) and light chains (LC) are already paired, there would
be no need to screen large libraries for correctly paired mAbs. Single B
cell cloning simpliﬁes the process to a single cloning and expression
step, bypasses themultiple rounds of panning/screening and the subse-
quent subcloning into mammalian expression vectors required by
display techniques. Only a single round of screening is required to select
the highest afﬁnity mAbs whose recombinant production will be then
accomplished by establishing high-producing stable cell lines. However,
the number of antibodies capable of being cloned and expressed using
this method is limited by traditional time- and effort-consuming
methods.
Cloning PCR ampliﬁed variable domain genes into an expression
vector typically requires growth on agar plates and screening of multi-
ple clones that contain the desired insert. Plating hundreds of bacterial
transformations on agar plates and screening multiple colonies from
each plate is extremely time consuming and low throughput. Further,
generating stable cell lines or performing large-scale or multiple
small-scale transient transfections to serve as a continuous source ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tical for dozens or hundreds of leadmAbs. An ideal mAb cloning and ex-
pression platform would contain a single high throughput cloning step
followed by rapid generation of a continuous source of recombinant
mAbs.
In this report, we describe a robust high-throughput mAb discovery
and production system that integrates the advantages of high-efﬁciency
cloning and stable pool selection methods, reducing the time and effort
required to clone and express large numbers of ampliﬁed V genes.2. Materials and methods
2.1. Plasmid construction
Monocistronic plasmids were generated from a customized pcDNA-
3.1-based plasmid where the HC or LC gene was cloned into a multiple
cloning site between a CMV promoter and SV40 polyA signal. The HC
plasmids contained the zeocin resistance gene under the control of the
SV40 promoter, and the LCplasmids contained the blasticidin resistance
gene under the control of the SV40 promoter.
Bicistronic plasmids were generated from a customized pcDNA-3.1-
based plasmid. A modiﬁed encephalomyocarditis virus (EMCV) IRES
with point mutations G375A and A484G to remove ApaI and HindIII
restriction sites, respectively, was fused at the 5′ end of a cDNA
conferring resistance to either blasticidin (B), hygromycin (H), neomycin
(N), puromycin (P), or zeocin (Z), by using overlapping PCR, and cloned
between the 3′ end of a multiple cloning site and a SV40 polyA signal.
The resulting plasmids were named pCIx, where x is B, H, N, P, or Z.
PCR was used to amplify a mouse immunoglobulin kappa leader
with 3′ restriction sites that overlapped 5′ restriction sites added to
human gamma and kappa constant (C) regions during PCR ampliﬁca-
tion. The leader and C regions were joined together by overlapping
PCR and cloned into the multiple cloning site of pCIx vectors to make
pCIx-leader-C region vectors (Fig. 1).
V region cDNAswere ampliﬁed by RT-PCR from RNA isolated from B
cells similar to Lightwood et al. (2006) with primers containing 15 base
pairs (bp) at the 5′ ends thatwere homologous to the signal sequence or
C region. An In-FusionHD cloning kit (Clontech)was used to clone the V
regions between the leader and C regions in restriction enzyme-
digested pCIx-leader-C region vectors (Fig. 2A).
For high-throughput cloning of variable regions, following addition
of SOC medium to the transformation and incubation at 37 °C for 1 h,
50 μL of each transformation pool was added to 1 mL Terriﬁc Broth in
a 2-mL 96-well deep well plate, and shaken overnight in a microtiter
plate shaker at 37 °C. Glycerol stocks were made from a portion of the
cultures and stored at −80 °C. The cultures were then processed for
small-scale plasmid DNA extraction (miniprep) with Qiagen's QIAGEN
Plasmid Plus 96 Miniprep Kit using an Eppendorf epMotion 5075 VAC.pCIx-ldr-gamma
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Fig. 1. Plasmid schematics for pCThe semi-clonal DNA was sequenced to conﬁrm the presence of the in-
sert in the vector.
To determine the efﬁciency of the In-Fusion reactions, severalmicro-
liters of the glycerol stocks were added to LB agar plus ampicillin plates
(Teknova) and streaked for isolation. Sixteen colonies from each plate
were PCR-screened by resuspending the colony in 5 μL of water and
adding 5 μL of Taq\\Pro Complete (Denville), 0.1 μL of a forward primer
homologous to the 5′UTR, and 0.1 μL of a reverse primer homologous to
the 5′ end of the IRES. Following PCR ampliﬁcation, the products were
analyzed on a 1% Tris-acetate-EDTA agarose gel.
Point mutations were introduced in heavy chain plasmids using a
QuikChange Lightning kit (Agilent) according to the manufacturer's
protocol.
2.2. Cell culture
Human embryonic kidney (HEK) FreeStyle 293-F cultures were
maintained in FreeStyle 293 expression medium (ThermoFisher) ac-
cording to the manufacturer's instructions. Cells were transfected by
seeding 1.8 × 107 cells in 30 mL medium in a 125-mL shake ﬂask one
day prior to transfection. On the day of transfection, 5 μg of each HC
and LC plasmids were combined with 65 μg PEI (linear, MW 25000;
Polysciences) in 1.5 mL OptiPro (Life Technologies). After incubation
at room temperature for 15 min, the PEI-DNA mixture was added to
3 × 107 cells in 30 mL medium in a 125-mL shake ﬂask. Cultures were
incubated at 37 °C in 8% CO2 with shaking at 125 rpm for 8 to 10 days.
Antibody-expressing stable pools were selected by adding 3 mL of
transfectants to 12 mL cDMEM (complete DMEM supplemented with
10% FBS, ThermoFisher) in a T75ﬂaskwith the appropriate pair of selec-
tion drugs (5 μg/mL blasticidin, 100 μg/mL hygromycin, 3 μg/mL puro-
mycin, 400 μg/mL zeocin [ThermoFisher], 400 μg/mL G418
[Calbiochem]) one to four days after transfection. After drug-resistant
cells grew to conﬂuency, the medium was replaced with FreeStyle 293
expression medium for 24 to 48 h. Cells were physically dislodged by
tapping the ﬂask (trypsinization resulted in low viability, data not
shown) and were then seeded at 6 × 105 cells/mL in 30 mL FreeStyle
293 expressionmedium in a 125-mL shakeﬂask. Cultureswere incubat-
ed at 37 °C in 8% CO2 with shaking at 125 rpm. After passaging the cells
three times, terminal cultures were set up by seeding cells at 1 × 106
cells/mL in 30 mL FreeStyle 293 expression medium in a 125-mL
shake ﬂask. Cultures were incubated at 37 °C in 8% CO2 with shaking
at 125 rpm for 10 days. It was found that when performing the drug se-
lection in a serum-containing static adherent culture, cells became drug
resistant much faster than when selected for resistance in a serum-free
suspension culture. There was no difference in mAb production be-
tween the two selection methods (data not shown).
Clonal cell lines were obtained by seeding 96-well plates with an av-
erage of 0.5 cells per well in cDMEM. After 3 to 4 days, conditioned
cDMEM from untransfected 293-F cells and drug selection to a ﬁnalpCIx-ldr-kappa
Selection Marker
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Fig. 2. In-Fusion cloning of variable region inserts. (A) HC and LC constant-region vectors were designed to contain a multiple cloning site between the leader sequence and the constant
region. An in-frame stop codon was included in the multiple cloning site (underlined) to mitigate translation of proteins lacking a variable region insert. The HC constant-region vectors
were cut with AfeI, PmeI, and EcoRV and LC vectors were cut with AfeI, EcoRV, and PmeI for linearization. Variable regions were PCR ampliﬁedwith 15-bp 5′ and 3′ ends homologous to the
vector. The variable region PCR fragmentswere fused to the vector by In-Fusion cloning. (B)Miniprepped pools of transformed E. coliwere digestedwith restriction enzymes to determine
the size of the antibody cDNA in the plasmid. Heavy chain plasmids with a variable region insert produced a ~1.4 kb fragment. Light chain plasmids that contain a variable region insert
produced a ~700 bp fragment. Heavy and light chain plasmids without inserts produce 1 kb and 250 bp fragments, respectively. The wells alternate between HC and LC, except the last 8
samples on the bottom row are all LC plasmids. Arrows indicate fragments with no insert. Asterisks indicate a mixture of fragments with and without inserts.
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After further incubation for several more days or weeks, wells containing
a single colonywere grown in 24-well or 6-well plates and eventually ex-
panded to T75 ﬂasks. Once conﬂuent, mAb expression of the clones was
determined by seeding 1 × 106 cells in 3 mL of cDMEM supplemented
with low-IgG FBS (ThermoFisher) for 7 days. The amount of mAb in the
mediumwas then quantitated. Cloneswere then adapted to FreeStlye293
medium and the amount of mAb expressed was quantitated as above.
2.3. Antibody quantitation
Antibody titer yieldswere quantiﬁed using anOctet QKwith Dip and
Read Protein A Biosensors (ForteBio) according to the manufacture's
protocol.3. Results
3.1. High throughput, semi-clonal platform for constructing recombinant
mAb expression plasmids
The biggest bottleneck in the cloning process of individual HCs and
LCs is the selection of recombinant transformants on antibiotic agar
plates and subsequent colony screening. To streamline the cloning pro-
cess, these steps were eliminated by utilizing the highly efﬁcient liga-
tion-independent In-Fusion HD cloning kit. In the In-Fusion HD
reaction, reactions rely on homologous recombination between the vec-
tor and insert to circularize the vector, and, therefore, there is little to no
background from religated vector. Furthermore, it was found that there
was little to no background colonies resulting from undigested plasmid
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between the leader and C region sequences (Fig. 2A; data not shown),
thereby making it possible to grow and miniprep transformations as a
semi-clonal pool.
To validate and quantify this method, 44 VH genes and 51 VL genes
were RT-PCR ampliﬁed from clonal B cell populations and cloned into
C region vectors. Minipreps of semi-clonal DNA pools were digested
with restriction enzymes that cut 5′ and 3′ to the leader and C region,
respectively, and analyzed on a 1% agarose gel. As predicted, HC plas-
mids with or without an insert yielded a ~1.4 kb or 1 kb fragment, re-
spectively, and LC plasmids with or without an insert yielded a
fragment at ~700 bp or 250 bp, respectively. The great majority of LC
plasmids (98%) and HC plasmids (95.4%) contained the expected insert
(Fig. 2B), while only few plasmids did not (arrows). Some of the HC
minipreps (6.8%) contained a mixture of plasmids with andwithout in-
serts (asterisks).
The percentage of plasmids with inserts in each transformation was
further quantitated by streaking out a small portion of the transforma-
tion on agar plates and screening individual colonies by PCR for the
presence of an insert. The percentage of clones with inserts varied
from 31% to 100% per transformation with an average of 71.6% for HC
plasmids and 81.1% for LC plasmids (Table 1). Thewide range of positive
clones was likely due to incomplete digestion of the vector by the re-
striction enzymes as subsequent experiments utilizing a different prep-
aration of vectors resulted in much higher percentage of positive clones
(data not shown).
This approach cannot only be applied to ligation-independent clon-
ing, but also to whole-plasmid ampliﬁcation-based mutagenesis of
heavy and light chain plasmids using methods such as the QuikChange
Lightning Site-Directed Mutagenesis kit. Several hundred site-directed
HC plasmid mutants were generated and the transformants were
miniprepped as semi-clonal pools as above. The semi-clonal DNA
preps were each sequenced for the presence of the point mutation(s).
All semi-clonal plasmid pools contained only the desired mutation(s)
(data not shown).
3.2. Bicistronic plasmid design and expression
Even though a large number of mAbs can be rapidly produced via
small-scale transient transfections for screeningpurposes, scalingup se-
lected mAbs post-screening to use for in vitro/in vivo studies can be
more challenging. Although several techniques to enhance sufﬁcient
production for biological studies have been described over the last sev-
eral years (Backliwal et al., 2008; Pham et al., 2006; Pham et al., 2003;
Sun et al., 2006), these methods do not yield a process for stable cell
line production to provide the continuous source of material required
for support of longer term development of candidate therapeutic or di-
agnostic mAbs. Similar to high-throughput cloning, the major bottle-
neck for generating stable mammalian cell lines is screening for high-
titer clones. This method typically selects for plasmid integration in
transfected cells by performing limiting dilution of the cells in growth
medium containing drug selection (Jostock and Knopf, 2012), a process
that is labor-intensive and requires between 4 and 6 months.
An alternativemethod utilizes selection of stable pools of cells. Here,
transfected cells are not subcloned and drug selection is applied to the
pool of transfected cells (Ye, 2012). Selection of a pool of mAb-express-
ing cells overcomes these hurdles since the expressing cell line is not
subjected to multiple rounds of screening. To avoid generating stable
cell pools with low antibody titers due to the abundance of non- orTable 1
The average percentages of inserts present in 42 heavy chain or light chain plasmids.
No. InFusion reactions No. colonies screened/react
HC 42 16
LC 42 16low-expressing antibiotic resistant cells, as seen in traditional ap-
proaches that utilize monocistronic expression plasmids (Ye et al.,
2010), bicistronic plasmids were designed to transcriptionally link ex-
pression of a drug resistance protein for blasticidin (blasticidin S deam-
inase, BSD), G418 (neomycin phosphotransferase, NPT), hygromycin
(hygromycin B phosphotransferase, HPH), puromycin (puromycin N-
acetyltransferase, PAC), or zeocin (bleomycin resistance protein, BRP)
to the expression of a HC or LC by an EMCV IRES on a single mRNA tran-
script (Fig. 1). The HC and LC for human (mAb1) and chimeric rabbitV-
humanC (mAb2)mAbs were cloned into both bicistronic pCIZ and pCIB
vectors, respectively, as well as monocistronic zeocin-resistance and
blasticidin-resistance vectors, respectively. Transient mAb expression
was reduced only 20–30% when the HC and LC were cotranslated with
antibiotic resistance genes from bicistronic mRNA when compared to
monocistronic mRNA (Fig. 3A). However, mAb expression from stable
pools was 2- to 3-fold higher for the bicistronic plasmids.
Single cell clones were subsequently isolated from the stable pools
via limiting dilution and tested for mAb titer yields. Up to forty clones
were analyzed for mAb expression in static culture (Fig. 3B). The aver-
age mAb titers for bicistronic clones were 1.5- to 2.5-fold higher than
monocistronic clones. The highest titer clones producing mAb1 and
mAb2were converted to serum-freemedium, and analyzed for produc-
tion yields in shaking cultures. Titers from clones using bicistronic ex-
pression plasmids were 2.2- to 2.4-fold higher than from
monocistronic expression plasmids (Fig. 3C).3.3. Pairing antibiotic resistance plasmids for maximal expression
To maximize mAb expression, the HC and LC genes are expressed
using separate plasmids. Therefore, obtaining stable cell lines that con-
sistently expressed both chains requires different resistant genes on
each plasmid. To determine the best combination of drug resistance
genes that may result in the highest mAb titers from both transient
transfections and stable pools, the HC and LC of mAb1 were cloned
into vectors that contained each drug resistance gene. Each HC plasmid
was cotransfected in a matrix format into FreeStyle 293-F cells with
each LCplasmid. Themedia from transient transfectionswere harvested
after ten days, and the amount of secreted mAb was analyzed (Fig. 4A).
Transient expression of themAbwas found to be inﬂuenced by the drug
resistance gene in the LC plasmid as clones exhibiting the lowest titers
(17–45 μg/mL) expressed NPT (pCIN) and HPH (pCIH) while those
with the highest-titers (66–75 μg/mL) expressed PAC (pCIP). These
data were observed in other studies as well (see below). There was no
correlation between mAb expression and the drug resistance gene
expressed by the HC plasmid.
The effect of antibiotic selection on the expression of mAb1 in stable
pools was determined by quantitating the amount of secreted mAb ten
days after seeding terminal cultures. In contrast to transient expression,
mAb production did not correlate to the drug resistance gene in the LC
plasmid. However, linking expression of BRP (pCIZ) to either the HC
or the LC resulted in the highest mAb titers (Fig. 4A).
To determinewhether zeocin resistance results in the best universal
expression, the HC and LC plasmids of two additional mAbs (mAb2
and ratV-mouseC chimeric, mAb3) were co-transfected as pCIB and
pCIZ, pCIH and pCIZ, pCIN and pCIZ, or pCIP and pCIZ combinations.
Transient expression of mAb2 and mAb3 was similar to mAb1 in that
the lowest titers were observedwith NPT- and HPH-expressing LC plas-
mids (Fig. 4B and C). There was little difference in transient expressionion Average % positive SEM
71.6% ± 3.7%
81.1% ± 3.2%
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Fig. 3. ComparingmAb expression frommonocistronic and bicistronicmRNA. TheHC and LC of human (mAb1) and rabbit-human chimeric (mAb2)mAbswere cloned intomonocistronic
plasmids and expressed. The HC and LC geneswere also cloned into bicistronic plasmidswhere the translation of the antibiotic resistance proteinwas from the samemRNA as theHC or LC
via an IRES sequence separating the HC or LC and the antibiotic resistance gene. (A) The expression of mAb1 and mAb2 from monocistronic or bicistronic plasmids in transiently
transfected 293-F cells using an Octet QK with protein A Biosensor tips 10–12 days post-transfection. Pools of 293-F cells stably expressing the mAbs were also analyzed for mAb
expression using an Octet QK with protein A Biosensor tips 7–10 days after seeding the terminal cultures. (B) Individual clones were isolated from the stable pools, and the expression
of each mAb in static culture was analyzed for expression as in (A). (C) Clonal cell lines were adapted to 293FreeStyle medium and culture in shake ﬂasks, and the expression of each
mAb was analyzed for expression as in (A). Average expression levels between the monocistronic and bicistronic cell lines in (B) and (C) was analyzed by Welch's unequal variances t-
test. ****p b 0.0001, *p= 0.0411.
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mL, respectively).
Stable pools were selected, and the trends in expression of mAb2
andmAb3 were similar to mAb1 (Fig. 4B and C). Although the puromy-
cin-resistant plasmids yielded the highest producing cell lines, a stable
pool could not be obtained from the mAb3 HC-puromycin/LC-zeocin
combination. Repeated attempts to generate a stable cell line from the
mAb3 HC-puromycin/LC-zeocin combination were not successful even
when the concentration of puromycin was reduced several fold. It was
also observed that all mAb1, mAb2, and mAb3 stable cell lines made
from any PAC-based plasmid took longer to grow to conﬂuency follow-
ing drug selection due to extreme sensitivity of 293-F cells to puromycin
(data not shown). Given the inconsistency of obtaining a stable cell line
from puromycin-resistant plasmids, these plasmids were deemed least
useful and not used for any further development.
For all three mAbs listed above, the stable pool generated from the
HC-blasticidin/LC-zeocin combination yielded the lowest-titers.
Although stable mAb expression from HC plasmids containinghygromycin or neomycin was relatively high, the transient expression
was rather low, limiting the usefulness of these plasmids. In addition, vi-
able mAb3 stable pools were not obtained for the HC-hygromycin/LC-
zeocin nor HC-zeocin/LC-neomycin combinations (Fig. 4B). Based on
these results we focused our efforts on the HC-zeocin/LC-blasticidin
plasmid combination platform since this format consistently yielded
high mAb titers from both transient transfections and stable pools.
3.4. Effects of increased or decreased selection pressure on mAb expression
Since mAb expression was linked to drug resistance, it was possible
that increasing the amount of antibiotics during selection could select
for cells that express higher amounts of the antibiotic resistance pro-
teins, and thereby higher levels of mAb. Varying concentrations of
blasticidin and zeocin were added during the mAb1 selection process
to evaluate this hypothesis. Unfortunately, increasing the concentration
of zeocin up to 1200 μg/mL or blasticidin up to 15 μg/mL did not yield
higher titer clones (Fig. 5A).
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Fig. 4. Antibody expression using IRES-linked antibiotic selection plasmids. Bicistronic IRES plasmids encoding various antibiotic resistant genes (B – blasticidin, H – hygromycin, N –
neomycin, P – puromycin, Z – zeocin) downstream of immunoglobulin HC or LC genes were co-transfected into 293-F cells, e.g. B-H is a blasticidin-HC plasmid cotransfected with a
hygromycin-LC plasmid. Various combinations of resistance genes and immunoglobulin HC and LCs were used including (A) human (mAb1), (B) rabbit-human chimeric (mAb2), or
(C) rat-human chimeric (mAb3) mAbs. Antibody titers were analyzed using an Octet QK with protein A Biosensor tips 10–12 days post-transfection for transient transfections or 7–
10 days after seeding the terminal cultures with stably selected cell lines.
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monitoring the expression of mAb1 over time. After the eighth passage
in 400 μg/mL zeocin and 5 μg/mLblasticidin, thepooled culturewas split
into three subcultures and cultured using decreasing amounts of drug
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ransfected 293-F cells were dually selectedwith varying concentrations of blasticidin (5 or
ools were analyzed after 7–10 days for antibody titers using an Octet QK with protein A
arter (1.25/100), or none (0/0) of the original concentration (5/400) and assayed every
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An exemplary workﬂow is detailed in Fig. 6. Herein the VH and VL
regions are RT-PCR ampliﬁed from individual single B cell cultures and
ligation-independently inserted into constant region vectors. The E.
coli transformation for each reaction is grown in liquid medium, rather
than plated for isolation of individual colonies. This shortens the cloning
process to 2 to 4 days from 1 to 2 weeks. The semi-clonal HC and LC
DNAs cloned from each B cell culture are cotransfected and a portion
of each transfection is selected as a pool in static serum-containing cul-
ture or serum-free shaking culture. Bypassing the need to select and
screen individual colonies, the semi-clonal transfectants are selected
within 7 to 11 days, as opposed to 4 to 5 weeks, and eliminates the ex-
pansion process, thereby save an additional 4 to 5weeks. During the se-
lection process the transient cultures can be screened for antigenTransient mAb 
production for screening 
antigen binding
Pairwise 96- or 24-well 
transfection of HCs & 
LCs from multiple B cel
Transfer portion of cells to 
select stable pools for scale-
or
VH cDNA
VL cDNA
RT-PCR variable regions 
from single B cell culture
B Cell
ligation-
independent
cloning
B
B
B
… etc.
Fig. 6. Flowchart for high throughput cloning,binding, and the topmAbs picked for serum-free adaptation and expan-
sion. The adaptation of the semi-clonal culture to serum-free medium
requires no subsequent rescreening formAb production, thereby saving
N3 weeks. In total, our semi-clonal method cuts the time from cloning
through stable cell line development by 3 to 5 months.
4. Discussion
In this report,we have described a rapid, optimized high-throughput
system for the cloning and expression of immunoglobulin VH and VL
cDNAs by utilizing the same plasmid for both transientmAb production
aswell as large-scale production by stably selected lines. Several groups
have demonstrated either high-throughput methods for cloning mAbs
(Dodev et al., 2014; Jones et al., 2010; Kurosawa et al., 2011; Liao et
al., 2009) or rapid generation of stable mAb-expressing cell lines, butls
up
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Sequence
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4-6 Weeks
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transfection, and stable cell line selection.
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platform. Indeed, the methods and vectors used in high-throughput
cloning methods are not amenable to rapid stable cell line production
as they are based on transfection of PCR products (Liao et al., 2009),
lack an antibiotic resistance gene (Dodev et al., 2014) or utilize
monocistronic plasmids (Jones et al., 2010; Kurosawa et al., 2011).
While, Ho et al. (Ho et al., 2012; Ho et al., 2013) demonstrated rapid
generation of stable pools expressing monoclonal antibodies in CHO
cells using a tricistronic plasmid where the HC, LC, and antibiotic resis-
tance gene were translated from a single transcript, this method re-
quires extra steps in the cloning process. Two rounds of cloning are
required to insert both the HC and LC into the plasmid. Alternatively, a
single cloning step can be used to insert a single PCR fragment contain-
ing an IRES sequence ﬂanked by the HC and LC. However, this method
requires an extra round of PCR to create the aforementioned PCR prod-
uct. Therefore, cloning the HC and LC into separate bicistronic expres-
sion plasmids provides the simplest and quickest means to generate
expression plasmids and stable cell lines.
One of the major advantages of this system is the ability to move
quickly a lead mAb to large-scale production by creating stable cell
pools using bicistronic expression plasmids that transcriptionally
linking expression of the HC and LC with antibiotic resistance genes.
In contrast to stable pools generated from monocistronic plasmids (Ye
et al., 2010), there is no need to sort cells for enrichment (Ye, 2012;
Ye et al., 2010) or subclone for high-producing cells (Jostock and
Knopf, 2012) since all antibiotic resistant cells theoretically express
themAb (Gurtu et al., 1996; Rees et al., 1996). Furthermore, this system
is amenable to the cloning and expression of a large number of other
types of recombinant proteins (e.g., surface antigens for high-through-
put target cell line generation).
Several steps have been eliminated to signiﬁcantly enhance the
cloning throughput while decreasing labor hours typically required for
high-throughputmAb discovery. A few areas for improvementwere ex-
perienced during this optimization process. Given that 20–30% of plas-
mids lacking an insert in the miniprep pool, it was possible that mAb
expression could be affected by either expression of aberrant leader-
constant domain protein or by diluting out the overall amount of in-
sert-containing plasmid. To minimize these issues, a stop codon was
engineered in the cloning site between the signal sequence and C region
(Fig. 2A). A V region insert replaces this stop codon so that only produc-
tivemAbs are translated. In addition, it has been shown that non-coding
DNA can supplement more than half of the coding DNA in a PEI-based
transfection with little effect on recombinant protein expression
(Kichler et al., 2005; Rajendra et al., 2012); data not shown). Even
though the presence of insert-null vector likely has little effect on over-
all mAb expression within a pooled culture, one could employ a zero-
background cloning strategy to ensure a cloning efﬁciency closer to
100% (Bernard, 1995; Bernard et al., 1994; Lund et al., 2014; Miyazaki,
2010; Parr and Ball, 2003; Schefer et al., 2014; Wang et al., 2014).
For recombinant mAb production, careful consideration was given to
the choice of cells used.While Chinese hamster ovary (CHO) cells are pre-
dominantly the cells of choice for the production of biopharmaceuticals,
HEK cells are much more popular for transient transfection due to their
inherent ease of transfection and high production from transient trans-
fections (Butler and Meneses-Acosta, 2012). Despite recent improve-
ments of the protocols to increase the expression levels of mAbs in
transient CHO transfections, these methods tend to involve additional
steps, including diluting cells several hours after transfection, adding
feed several hours or days post-transfection, decreasing the incubation
temperature, and/or performing multiple rounds of transfections
(Chusainow et al., 2009; Codamo et al., 2011; Pichler et al., 2011;
Rajendra et al., 2015; Rajendra et al., 2011; Reisinger et al., 2009;
Wulhfard et al., 2008). As these additional manipulations increase effort
and cost, we decided that the use of HEKs would be most ideal for at
least transient expression. It can be argued that the cell type used during
mAb characterization should be the same cell type used to manufacturethe therapeuticmAb due to differences in post-translationalmodiﬁcation
differences (e.g. glycosylation). However, a recent report demonstrated
that the mAbs produced by transient HEK transfections correlate with
stable CHO cell lines in regards to mAb titers and the quality of the prod-
uct (Diepenbruck et al., 2013). Given this observation and as the intended
use of this systembeing the expression ofmAbs for primary candidate se-
lection, any differences between HEK-derived mAbs versus CHO-derived
mAbs are negligible.
Interestingly, our ﬁndings that the choice of antibiotic resistance
gene pairings inﬂuences themAb expression offers future opportunities
to test other selection markers for even higher titers than is achieved in
our current optimal system. Importantly, while our ﬁndings that resis-
tance to zeocin was essential in obtaining a high expressing pool were
similar to Lanza et al. (2013), we found, in contrast to Lanza et al., no ad-
vantage in maintaining drug selection after primary selection for up to
eight weeks. Therefore, drug selection can be removed while scaling
up the culture for mAb production, providing a distinct advantage
over stable pools selected from monocistronic plasmids which require
maintenance of drug selection during scale-up (Ye, 2012).
In conclusion, we outline an antibody cloning and screening system
that can facilitate the cloning, expression, and screening of up to a thou-
sand mAbs, which may be expandable using automation. By removing
the bottlenecks described here, the time from isolating V-region cDNA
to producing large-scale mAbs from stable pools has been reduced
from 4 to 6 months to only 4 to 6 weeks.
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